To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses

Obesity Clinical Trial

Official title:

A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 After Administration of Multiple Ascending Doses

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01469923
• Other study ID #: D3870C00002
• Status: Terminated
• Phase: Phase 1
• First received: September 30, 2011
• Last updated: July 23, 2012
• Start date: March 2012
• Est. completion date: December 2012

Study information

• Verified date: July 2012
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This is a randomised and single-blind, placebo-controlled study to investigate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of repeated and ascending doses of AZD2820 to obese but otherwise healthy male subjects.

Description:

A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 after Administration of Multiple Ascending Doses.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures including the genetic sampling and analyses

• Obese but otherwise healthy male subjects aged 18 - 45 years with suitable veins for cannulation or repeated venepuncture

• Male subjects should be willing to use barrier contraception ie, condoms, from the first day of dosing until 3 months after the last dose of investigational product

• Have a body mass index (BMI) between 27 and 40 kg/m2

Exclusion Criteria:

• History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the stud

• A history of erectile dysfunction or anatomic abnormality of the penis (eg, cavernosal fibrosis, Peyronie's disease, or plaques) which interferes with normal erectile function

• Prolonged QTcF >450 ms or shortened QTcF <340 ms or family history of long QT syndrome

• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD2820

• Any clinically significant abnormalities in clinical chemistry, haematology (including eosinophilia) or urinalysis results as judged by the investigator

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Obesity

Intervention

Drug:
• AZD2820
Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
• Placebo
Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen

Locations

Country	Name	City	State
United Kingdom	Research site	London

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Description of the safety and tolerability profile of AZD2820 in terms of adverse events.	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis.	From baseline, defined as day 1 of dosing, up to day 29	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of labolatory data ( clinical chemistry, haematology and urinalisys).	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis.	From baseline, defined as one day prior first dose, up to day 28.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of vital signs ( pulse, systolic and diastolic blood preassure ( SBP, DBP and 24h ambulatory BP), body temperature).	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis.	From baseline, defined as one day prior first dose, up to day 29.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of total immunoglobulin levels.	Number of subjects with immunoglobuline level outsite of reference range. No formal statistical tests will be performed. Abnormalities will be listed without statistical analysis.	From baseline, defined as one day prior first dose, up to day 44.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of safety electrocardiogram (ECG).	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis	From baseline, defined as last pre dose measurement, up to day 28.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of digital electrocardiogram (ECG).	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis. The QT correction factor will be based on the Fridericia's formula.	From baseline, defined as assessment at screening visit and day 1 of dosing.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of electroencephalography (EEG).	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis.	From baseline, defined as mean value of the 10 minutes recording prior first dose up to 7th day of dosing.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of Columbia-Suicide Severity Rating Scale (C-SSRS).	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis.	From baseline, defined as one day prior first dose, up to day 12th of dosing.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of skin pigmentation.	No formal statistical test will be performed.	From baseline, defined as one day before first dose, up to day 29.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of Penile erection (measured by Rigiscan).	No formal statistical test will be performed.	From baseline, defined as one day before first dose, up 12th day of dosing.	Yes
Primary	Description of the safety and tolerability profile of AZD2820 in terms of physical examination.	No formal statistical test will be performed. Abnormalities will be listed without statistical analysis.	From baseline, defined as two days prior first dose, up to day 29.	Yes
Secondary	Change in total caloric intake from baseline.	Change from baseline will be measured after each meal and then grafically presented.	From baseline, defined as one day prior first dose to end of treatement which is day 15.	No
Secondary	Description of the PK profile of AZD2820 in terms of Cmax, AUC(0-tau), AUC(0-t), AUC, (t1/2lz, h).	Maximum drug plasma concentration (Cmax), Area under the drug plasma concentration-time curve from zero to the end of the dosing interval (AUC(0-tau), Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration (AUC(0-t)), Area under the plasma concentration time curve from zero to infinity (AUC), Terminal half-life (t1/2lz, h).	Day 1, PK samples collected post-dese at 20 min, 40 min, 1hr, 1.20hr, 1.40hr, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 18hrs and 24hrs.	No
Secondary	Description of PK profile of AZD2820 in terms of (Css,max, nmol/L), AUCss,(0-tau), (t1/2lz).	Maximum plasma concentration at steady state (Css,max, nmol/L), Area under the plasma concentration-time curve from zero to the end of the dosing interval at steady state (AUCss,(0-tau)), Terminal half-life (t1/2lz).	Day 7, PK samples collected post-dese at 20 min, 40 min, 1hr, 1.20hr, 1.40hr, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 18hrs and 24hrs.	No